Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer

Figure 1 Comparison of overall survival and progression-free survival between the two groups. A: Overall survival; B: Progression-free survival. P-SOX: Nab-paclitaxel and oxaliplatin + S-1; SOX: Standard S-1 and oxaliplatin; HR: Hazard ratio; PFS: Progression-free survival; OS: Overall survival.

Figure 2 Progression-free survival nomogram (Nab-paclitaxel and oxaliplatin + S-1). PFS: Progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor Regression Grade.

Figure 3 Progression-free survival receiver operating characteristic curve. A: Sensitivity; B: Concordance index. AUC: The area under the operating characteristic curve.

Figure 4 Calibration curve for progression-free survival. PFS: Progression-free survival.

Figure 5 Decision curve analysis curves of progression-free survival. A: 1 year; B: 2 years; C: 3 years.

Figure 6  Kaplan-Meier survival curves for the verification of risk stratification.

Figure 7  Kaplan-Meier survival curves for the verification of risk stratification. PFS: Progression-free survival; HR: Hazard ratio.